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Abstract
Aims/hypothesis Translation of genetic association signals
into molecular mechanisms for diabetes has been slow. The
glucokinase regulatory protein (GKRP; gene symbol
GCKR) P446L variant, associated with inverse modulation
of glucose- and lipid-related traits, has been shown to alter
the kinetics of glucokinase (GCK) inhibition. As GCK
inhibition is associated with nuclear sequestration, we
aimed to determine whether this variant also alters the
direct interaction between GKRP and GCK and their
intracellular localisation.
Methods Fluorescently tagged rat and human wild-type
(WT)- or P446L-GCKR and GCK were transiently trans-
fected into HeLa cells and mouse primary hepatocytes.
Whole-cell and nuclear fluorescence was quantified in
individual cells exposed to low- or high-glucose conditions
(5.5 or 25 mmol/l glucose, respectively). Interaction
between GCK and GKRP was measured by sensitised
emission-based fluorescence resonance energy transfer
(FRET) efficiency.
Results P446L-GKRP had a decreased degree of nuclear
localisation, ability to sequester GCK and direct interaction
with GCK as measured by FRET compared with WT-
GKRP. Decreased interaction was observed between WT-
GKRP and GCK at high compared with low glucose, but
not between P446L-GKRP and GCK. Rat WT-GKRP and
P446L-GKRP behaved quite differently: both variants
responded to high glucose by diminished sequestration of
GCK but showed no effect of the P446L variant on nuclear
localisation or GCK sequestration.
Conclusions/interpretation Our study suggests the common
human P446L-GKRP variant protein results in elevated
hepatic glucose uptake and disposal by increasing active
cytosolic GCK. This would increase hepatic lipid biosyn-
thesis but decrease fasting plasma glucose concentrations
and provides a potential mechanism for the protective effect
of this allele on type 2 diabetes risk.
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Abbreviations
GKRP Glucokinase regulatory protein
hGKRP Human GKRP
rGKRP Rat GKRP
GCK Glucokinase
ECFP Enhanced cyan fluorescent protein
EGFP Enhanced green fluorescent protein
EYFP Enhanced yellow fluorescent protein
FRET Fluorescence resonance energy transfer
FRETN Sensitised emission-based FRET efficiency
F6P Fructose 6-phosphate
F1P Fructose 1-phosphate
WT Wild-type
SNP Single nucleotide polymorphism
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The past 4 years have seen a rapid expansion in the number
of reproducibly associated loci for type 2 diabetes and
related traits. However, progress in translating these genetic
associations into biological mechanisms for disease has
been slow [1, 2]. Contributing factors have included small
effect sizes and the mapping of association signals to poorly
annotated, often intergenic, sequences [3]. Signals that
include an obvious (e.g. non-synonymous) variant in a
biologically plausible gene provide tractable targets for
functional follow-up and a framework for exploring
approaches to variant characterisation [2].
Glucokinase (GCK) regulates glucose storage and
disposal in the liver. Hepatic GCK activity is modulated
by glucokinase regulatory protein (GKRP; gene symbol
GCKR), a competitive inhibitor of GCK. Fructose 6-
phosphate (F6P) and fructose 1-phosphate (F1P) enhance
and reduce GKRP-mediated inhibition, respectively [4, 5].
A further layer of regulation exists in the form of cellular
localisation: GKRP sequesters GCK to the nucleus at low
glucose concentrations, further inhibiting GCK activity and
glycolysis [6]. At higher glucose concentrations, glucose-
mediated dissociation of GCK from GKRP activates GCK
and exposes its nuclear export signal [7, 8].
Ac o m m o nGCKR single nucleotide polymorphism
(SNP) (rs1260326 [c.1337C>T; p.P446L]) has been repro-
ducibly associated with an inverse relationship between
glucose and triacylglycerol levels [9]. This seemingly
paradoxical relationship also extends to other glucose- and
lipid-related traits. The glucose-lowering leucine allele is
also associated with decreased fasting insulin, HOMA-
estimated insulin resistance and reduction of type 2 diabetes
risk [10] but increased triacylglycerol and total cholesterol
levels [11]. This variant is one of only a handful of
candidate non-synonymous variants identified to date from
type 2 diabetes association studies [2, 12]. We have
previously shown that variant P446L-GKRP increases
GCK activity as a result of diminished regulation by F6P
and have proposed that this results in increased hepatic
glycolytic flux and de novo lipogenesis, accounting for the
observed associated phenotypes [12]. Interestingly, this
kinetic effect was not seen with rat P446L-GKRP [13],
likely due to species differences in regulation by F6P [14].
However, kinetic mechanisms alone are not sufficient to
explain GKRP regulation of GCK in vivo. For example,
Gckr-knockout mice display impaired postprandial glucose
handling and paradoxical reductions in GCK protein levels
and activity in spite of the removal of GKRP inhibition [15,
16]. This suggests that nuclear interaction with GKRP plays
an important role in regulating GCK protein concentration
and stability and is essential for the maintenance of glucose
homeostasis. In addition, the P446L variant is associated
with inverse modulation of fasting and 2 h glucose levels,
an observation not readily explained by kinetic data [10].
As the contribution of GKRP and GCK cellular localisation
to phenotypes associated with the P446L-GKRP variant
protein is currently unexplored, the aims of the current
study were to assess the impact of this variant on the ability
of GKRP to sequester GCK in the nucleus and to further
explore potential differences between rat and human
regulatory proteins.
Methods
Cloning of fluorescent fusion plasmids Human GCK
(Mammalian Gene Collection; ATCC, Manassas, VA,
USA) was amplified using primers containing BamHI and
HindIII restriction sites and subcloned into the pEGFP-c3
vector encoding enhanced green fluorescent protein
(EGFP). Generation of enhanced cyan fluorescent protein
(ECFP)-tagged GCK (pECFP-GCK) has been described by
Baltrusch et al. [17]. PCR primers containing Eco47III and
EcoRI sites were used to amplify human GCKR (Mamma-
lian Gene Collection) and replace rat Gckr in pEYFP-N1-
GCKR [17]. The P446L mutation was introduced into rat
and human pEYFP-N1-GCKR plasmids by PCR-based site-
directed mutagenesis (Agilent Biotechnologies, Santa
Clara, CA, USA). The enhanced yellow fluorescent protein
(EYFP) in both rat and human pEYFP-N1-GCKR [17] was
replaced by mCherry [18] using AgeI and BsrGI restriction
sites. Two independent preparations of all plasmids were
generated and verified by sequencing. Primer sequences are
available upon request.
Cell culture and transient transfection of HeLa cells HeLa
cells were grown in DMEM with 5.5 or 25 mmol/l glucose
supplemented with 10% (vol./vol.) dialysed fetal bovine
serum and penicillin/streptomycin (all Invitrogen, Carlsbad,
CA, USA). For quantitative fluorescence microscopy,
4×10
4 cells were seeded into four-chamber slides (BD
Biosciences, San Jose, CA, USA) and cultured for 24 h.
Co-transfection of mCherry-GCKR and EGFP-GCK was
initially carried out with a range of plasmid DNA
concentrations at ten separate GCK/GCKR molar ratios
between 40:1 and 1:40. Nuclear localisation of GCK was
observed for GCK/GCKR ratios between 1:1 and 1:40. A
ratio of 1:4 was used for all future experiments as this is in
agreement with the published GCK/GCKR mRNA ratio in
liver [12]. Optimal transfection efficiency and fluorescence
intensity was observed with transfection of 100 ng total
DNA and 0.75 μl of Lipofectamine 2000 (Invitrogen).
Transfection was carried out according to the manufac-
turer’s instructions at 5.5 mmol/l glucose. The medium was
replaced 5 h after transfection.
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post-transfection and fixed with formaldehyde 24 h post-
transfection for mounting with VectaShield Mounting Medium
with DAPI (Vector Laboratories, Burlingame, CA, USA). Each
preparation condition was transfected two times. For fluores-
cence resonance energy transfer (FRET) studies, cells were
seeded at a density of 2×10
5 cells on 35 mm glass-bottom
dishes (MatTek, Ashland, MA, USA) and grown for 24 h.
Thereafter, cells were transfected with 1 μgD N A( 1 : 1r a t i oo f
the EYFP and ECFP plasmid) and 2 μl jetPEI (Qbiogene,
Montreal, QC, Canada) according to the manufacturer’s
instructions. The culture medium was replaced 1 day after
transfection, and the cells were incubated for another 24 h
with medium containing 5.5 or 25 mmol/l glucose.
Hepatocyte isolation, culture, and transient transfection
Primary hepatocytes were isolated from C57/BL6 mice using a
modification of the collagenase perifusion methods of Seglen
[19] and Bader et al. [20]. Isolated cells were suspended in
Williams’ medium E supplemented with 10 mmol/l glucose,
5% (vol./vol.) fetal calf serum, 1×10
−4 mmol/l dexametha-
sone, and 1×10
4 pmol/l insulin. Hepatocytes were seeded at a
density of 4×10
5 cells on 35 mm collagen-coated glass-
bottom dishes (MatTek, Ashland, MA, USA) or on 12-well
plates and incubated for 24 h in a humidified atmosphere at
37°C and 5% CO2. Cells were transfected with 1 μg DNA
(either EYFP plasmid alone or 1:1 ratio of the EYFP and
ECFP plasmid) and 3.2 μl PromoFectine Hepatocyte (Pro-
moCell, Heidelberg, Germany) according to the manufac-
turer’s instructions. Thereafter, hepatocytes were cultured for
24 h and finally incubated in medium with either 5.5 or
25 mmol/l glucose for 2 h.
Fluorescence microscopy and image analysis Confocal
images were acquired using a Zeiss LSM 510 NLO Meta
system mounted on a Zeiss Axiovert 200M microscope
with an oil-immersion Plan-Apochromat 63×/1.4 DIC
objective lens. Excitation wavelengths of 488 nm (2%),
561 nm (5%) and 770 nm (3%) were used for detection of
EGFP-GCK, mCherry-GKRP and DAPI, respectively.
Confocal images were post-processed using the MediaCy-
bernetics Image-Pro Plus v7.0 software package (Bethesda,
MD, USA) with a custom macro designed to calibrate,
segment (nuclei touching the image border were not
included) and outline the nuclei, outline the cell border,
count and record measurements. Measurements included
nucleus and cell areas (square micrometres) and fluorescent
intensity (minimum, maximum, mean, standard deviation
and sum). The nuclei outlines were obtained by using DAPI
staining as the template and propagating that outline
throughout the green and red channels. The cell border
outlines were obtained using the green and red signals.
Twenty independent transfection control images numbering
324 total nuclei were processed, along with 143 co-
transfection images totalling 1,472 nuclei. To address the
possibility that differences in localisation might be driven
by differences in fluorescence intensity between variants,
cells were also divided into four groups matched for either
whole-cell mCherry fluorescence intensity, EGFP fluores-
cence intensity or the ratio of mCherry/EGFP intensity in
individual cells.
For FRET experiments, a cellR/Olympus IX81 inverted
microscope system (Olympus, Hamburg, Germany)
equipped with a Cellcubator was used, as described by
Langer et al. [21]. HC436/24-458BS-HC483/32 and
HQ500/24-520BS-D542/27 single-band filter sets were
used for ECFP and EYFP, respectively (AHF Analysen-
technik, Tübingen, Germany). For FRET analyses, ECFP
and EYFP emission were detected simultaneously using a
DV-CC Dual View Simultaneous Imaging System (Optical
Insights, LLC, Tucson, AZ, USA) equipped with a 505
dcxr beam splitter and D472/30 and HQ542/27 emission
filters (AHF Analysentechnik). For FRET analyses and
calculation of the ECFP nuclear:cytoplasmic ratio, glass-
bottom dishes were fixed on the microscope stage and
images were obtained with an UPLSAPO 60×1.35 numer-
ical aperture oil-immersion objective (Olympus). For
calculation of the EYFP nuclear to cytoplasmic ratio on
12-well plates, an UPLSAPO 20×0.75 numerical aperture
objective (Olympus) was used and all motorised devices of
the microscope system were synchronised by the scanR
acquisition software (Olympus). The image focus was
automatically determined with a gradient method from
transmitted light images. Finally, the mean fluorescence
was calculated as average grey value in selected regions in
the nucleus and cytoplasm in individual cells after
background correction. The sensitised emission-based
FRET efficiency (FRETN) was calculated from the ECFP
emission with excitation at 436 nm, EYFP emission with
excitation at 436 nm and EYFP emission with excitation at
500 nm, based on the calculation of Vanderklish et al. [22].
FRETN measurements were validated using an ECFP-
EYFP fusion construct as described by Langer et al. [21].
Statistical analysis Statistical analyses were performed by
ANOVA followed by Bonferroni’s test for multiple com-
parison or t tests for independent samples using the Prism
analysis program (Graphpad, San Diego, CA, USA). Data
are presented as means±SEM. p values <0.05 (two-tailed)
were considered significant.
Results
Localisation of GKRP fluorescent fusion proteins in HeLa
cells and mouse primary hepatocytes To investigate the
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effect of the P446L variant on this localisation, mCherry-
tagged GCKR fusion plasmids were transiently transfected
into HeLa cells. HeLa cells were chosen as an established
model known to exhibit efficient glucose uptake and
lacking endogenous expression of GCKR and GCK [7,
23]. Both wild-type (WT)-hGKRP and P446L-hGKRP
localised strongly to the nucleus, but an appreciable
increase in cytoplasmic fluorescence intensity was detect-
able for P446L-hGKRP (Fig. 1a,b). To quantify this
apparent difference in localisation, the ratio of nuclear to
whole-cell fluorescence in individual cells was calculated.
Cells with very low EGFP or mCherry fluorescence
intensities (<50,000 arbitrary fluorescence units) were
excluded from statistical analysis. However, exclusion of
these data did not change the significance of any result.
WT-hGKRP (n=20 cells) was associated with significantly
increased nuclear localisation when compared with P446L-
hGKRP (n=21) (83.4±1.4% nuclear localisation compared
with 65.1±3.1%, mean±SEM; p<0.001; Fig. 1c). Previous
studies have revealed substantial kinetic differences be-
tween human and rat GKRP (rGKRP) [14]. However, no
studies have compared cellular localisation between rat and
human regulatory proteins. Accordingly, we also generated
and transiently transfected mCherry-tagged rat Gckr. The
P446L variant was also introduced into the rat Gckr
sequence. There was no significant difference in the
nuclear-to-whole-cell-fluorescence ratio of WT-rGKRP
(62.8±2.3%; n=20) and P446L-rGKRP (56.3±1.5%;
n=26; Fig. 1d). Both WT-rGKRP and P446L-rGKRP
showed significantly decreased nuclear localisation com-
pared with WT-hGKRP (p<0.001; ANOVA/Bonferroni
correction). Localisation of all GKRPs was independent of
glucose concentration (p>0.1; data not shown).
To confirm our observations in HeLa cells in a
physiologically relevant primary cell type, we assessed the
localisation of transiently transfected human and rat GKRPs
in primary mouse hepatocytes (Fig. 1d). EYFP-WT-hGKRP
(nuclear/cytoplasmic ratio 5.94±0.40; n=45 individual
cells) was again significantly associated (p<0.001) with
increased nuclear localisation compared with EYFP-P446L-
hGKRP (4.16±0.25; n=52), EYFP-WT-rGKRP (3.37±0.17;
n=36), and EYFP-P446L-rGKRP (3.45±0.18; n=37).
Localisation of all GKRPs was independent of glucose
concentration.
Co-transfection of human fluorescent GCK and GKRP
fusion plasmids in HeLa cells Transiently transfected
human EGFP-GCK localised entirely to the cytoplasm of
HeLa cells (Fig. 2a). In accordance with previous in vivo
studies, localisation was not affected by glucose concentra-
tion (data not shown) [15]. Co-transfection of GCK and
human or rat WT- and P446L-GKRP resulted in nuclear
sequestration of GCK (Fig. 2b,c). Incubation for 2–16 h at a
series of glucose concentrations (1–25 mmol/l) resulted in a
mix of nuclear and cytoplasmic localisation for both GKRP
and GCK (data not shown). Complete glucose-dependent
export of GCK was not observed even at high glucose
concentrations, consistent with previous observations in rat
hepatocytes [17, 24]. Accordingly, quantitative image
analysis was undertaken at two glucose concentrations
(5.5 and 25 mmol/l glucose) which have been previously
used to investigate the GCK:GKRP interaction as they are
either side of the glucose S0.5 (substrate concentration
needed for half maximal rate) for GCK (approximately
7.5 mmol/l) [17].
Quantitativeanalysiswas undertakenona total of787cells
from two transfections per glucose concentration and from
two independent plasmid preparations per variant. In the
presence of GCK at 5.5 mmol/l glucose, P446L-hGKRP was
againassociatedwithdecreasednuclearlocalisationcompared
with WT-hGKRP (Fig. 2d; 67.4±2.5% vs 73.6±1.8%
Fig. 1 Localisation of GKRP fluorescent fusion proteins at
5.5 mmol/l glucose. Visualisation of mCherry-WT-hGKRP (a)o r
P446L-hGKRP (b) and overlap with DAPI on transient transfection into
HeLa cells. c Quantification of degree of nuclear fluorescence for
human and rat GKRPs in HeLa cells. Data are expressed as means±
SEM of two individual experiments with a total of 20–26 cells
analysed.d Quantification of nuclear/cytoplasmic ratio of human and rat
GKRPs on transient transfection into primary mouse hepatocytes. Data
are expressed as means±SEM of two individual experiments with a
total of 36–52 cells analysed. ***p<0.001 compared with WT-hGKRP
(ANOVA/Bonferroni correction)
Diabetologia (2012) 55:114–122 117nuclear fluorescence; p=0.04). Human GCK showed signif-
icantly decreased nuclear localisation in the presence of
P446L-hGKRP (Fig. 2d; 57.5±2.1% vs 80.4±1.8% nuclear
fluorescence; p<0.001). The nuclear localisation of GCK
remained significantly reduced in the presence of P446L-
hGKRP compared with WT-hGKRP when individual cells
were matched for mCherry, EGFP or mCherry:EGFP
fluorescence intensity (p<0.05 for all groups).
There was no significant difference in GCK sequestration
between high and low glucose for either human variant
(Fig. 3). The differences in GCK sequestration between WT-
hGKRP and P446L-hGKRP observed at 5.5 mmol/l glucose
were also detectable at 25 mmol/l glucose (p<0.001 for
GKRP and GCK localisation). By comparison, transient co-
transfection of rGKRP proteins with human GCK resulted in
no difference in GCK sequestration between WT-rGKRP and
P446L-rGKRP (p>0.1 for both glucose concentrations).
However, there was a significant glucose dependence in
GCK sequestration by both rGKRPs, with increased GCK
nuclear localisation observed at low glucose (Fig. 3; p<0.05
for both WT-rGKRP and P446L-rGKRP). These findings are
not likely due to differences in rat and human GCK, as
previous kinetic studies have extensively characterised the
interaction between rat and human GKRP and either rat or
human GCK, showing no difference in interaction of GKRP
with either rat or human GCK [14].
Fig. 2 Localisation of co-
transfected human GCK and
GKRP in HeLa cells at
5.5 mmol/l glucose. a Visual-
isation of human EGFP-GCK
and DAPI. b,c Co-transfection
of mCherry-WT-hGKRP and
EGFP-GCK (b) or mCherry-
P446L-hGKRP and EGFP-GCK
(c): GKRP signal, upper left;
GCK signal, upper right; DAPI,
lower left; overlay, lower right.
d Quantification of degree of
nuclear fluorescence of GKRP
and GCK. Data are expressed as
means±SEM of two individual
experiments with a total of 77–
98 cells analysed. *p<0.05;
***p<0.001 (t test). Black bars,
GKRP; white bars, GCK
Fig. 3 Glucose dependence of GCK localisation in HeLa cells. Degree
of nuclear localisation of human GCK transiently transfected in the
presence of WT-hGKRP, P446L-hGKRP, WT-rGKRP or P446L-rGKRP
at 5.5 mmol/l and 25 mmol/l glucose. Data are expressed as
means±SEM of two individual experiments with a total of 18–98
cells analysed. *p<0.05; ***p<0.001 (ANOVA/Bonferroni correction).
White bars, 5.5 mmol/l glucose; black bars, 25 mmol/l glucose
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cells FRETN was used to detect the interaction between
ECFP-GCK and EYFP, EYFP-WT-hGKRP, or EYFP-
P446L-hGKRP in the nucleus of HeLa cells. FRETN
measures the transfer of energy from ECFP to EYFP on
excitation of ECFP and occurs when these proteins are
within close proximity (<10 nm) because of the overlap of
the emission spectrum of ECFP and the excitation spectrum
of EYFP [22]. There was a significant reduction in
interaction with GCK for the P446L-hGKRP variant
protein compared with WT-hGKRP at 5.5 mmol/l glucose
(Fig. 4). WT-hGKRP showed significantly reduced interac-
tion with GCK at 25 mmol/l glucose compared with
5.5 mmol/l. There was no significant glucose dependence
of interaction for P446L-hGKRP.
Direct interaction and cellular localisation of human GCK
and GKRP in primary mouse hepatocytes To compare
these results with those with primary cells, we assessed the
localisation and interaction of transiently transfected human
GCK and hGKRP in mouse hepatocytes. The importance of
endogenous mouse GCK and GKRP in this cell type was
emphasised by our observation that transfected ECFP-GCK
localises strongly to the nucleus at 5.5 mmol/l glucose and
translocates to the cytoplasm in a glucose-dependent
manner in the absence of transfected hGKRP (Fig. 5a).
Translocation of ECFP-GCK was not abolished by the
presence of EYFP-WT-hGKRP. However, EYFP-P446L-
hGKRP abolished glucose-dependent translocation of
ECFP-GCK. This may be due to an abundance of EYFP-
P446L-hGKRP protein in the cytoplasm preventing GCK
from localising to the nucleus even at low glucose concen-
trations, as suggested by our assessment of GCK localisation in
HeLa cells (Fig. 3). As in HeLa cells, we observed
significantly decreased interaction between GCK and P446L-
hGKRP compared with WT-hGKRP at 5.5 mmol/l glucose in
hepatocytes (Fig. 5b). At 25 mmol/l glucose in hepatocytes,
accelerated metabolism results in generation of high levels of
NADH and NADPH, resulting in autofluorescence. Addition-
ally, there is a reduction in the absolute value of FRETN
compared with HeLa cells due to quenching by endogenous
mouse GCK and GKRP. Accordingly, the reduced interaction
b e t w e e nG C Ka n dG K R Pa t2 5m m o l / lg l u c o s ew a sn o t
significantly detectable above this increased background
(Fig. 5b).
Discussion
To capitalise on recent advances in our understanding of the
genetic basis of diabetes risk, it is necessary to translate
association signals into detailed molecular mechanisms that
may underlie disease predisposition. We have previously
shown that P446L-hGKRP, inversely associated with
triacylglycerol levels and glucose levels, affects GCK
activity in liver through diminished regulation by F6P
[12]. However, the impact of this variant on the cellular
localisation of GCK and GKRP has not previously been
explored. Recent studies using rat hepatocytes have
suggested reliable estimation of GCK localisation can be
accomplished by quantification of localisation in multiple
fields of cells [25, 26]. We therefore sought to image a large
number of cells using a quantitative method to assess
nuclear and cytoplasmic fluorescence, and to combine this
with assessment of direct interaction of GKRP and GCK by
measuring FRETN. We have demonstrated for the first time
differences in the degree of nuclear sequestration of GCK
between WT-hGKRP and P446L-hGKRP and in the direct
cellular interaction of P446L-hGKRP with GCK compared
with WT-hGKRP. In spite of the presence of endogenous
mouse GCK and GKRP, we were also able to demonstrate
these differences in localisation, sequestration and direct
interaction in primary mouse hepatocytes.
In combination with our previously described kinetic
studies, the P446L-hGKRP variant protein would be
expected to result in an increased pool of active cytoplas-
mic GCK, particularly in the presence of low (i.e. fasting
state) glucose concentrations. Our findings suggest a
mechanism of action for P446L-hGKRP consistent with
the associated clinical phenotypes [9–11]. The reduced
ability of P446L-hGKRP to sequester and interact with
Fig. 4 Direct interaction between human GCK and WT-hGKRP or
P446L-hGKRP in HeLa cells. HeLa cells were transiently transfected
with plasmids encoding ECFP-GCK and EYFP, EYFP-WT-hGKRP or
EYFP-P446L-hGKRP as indicated and cultured in medium with 5.5
or 25 mmol/l glucose. Thereafter, fluorescence images were taken in
living cells and the FRETN was calculated from the ECFP and
EYFP emission intensities in the nucleus. Data are expressed as
means±SEM of two individual experiments with a total of 7–10 cells
analysed; *p<0.05; ***p<0.001 (ANOVA/Bonferroni correction).
White bars, 5.5 mmol/l glucose; black bars, 25 mmol/l glucose
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increased hepatic glucose disposal, glycolytic flux and
generation of precursors for synthesis of molecules such as
triacylglycerols and cholesterol. Recent findings associating
GCKR with increased VLDL particle concentrations [27]
suggest this enhancement of glycolytic flux leads to
increased levels of de novo triacylglycerol and cholesterol
synthesis and export.
Increased fasting-state hepatic glucose uptake, use and
disposal by GCK in the presence of P446L-hGKRP would
be predicted to decrease circulating plasma glucose con-
centrations. Further support for this molecular mechanism
comes from at least one cellular study linking over-
expression of GCK in liver to reduced glucose levels and
raised triacylglycerol levels [28]. We propose that de-
creased fasting plasma glucose levels could result in
decreased basal insulin output by the pancreas, which could
ultimately contribute to higher insulin sensitivity and
decreased risk of type 2 diabetes in spite of increased
hepatic lipid production.
Our results also suggest that, compared with WT-
hGKRP, P446L-hGKRP shows reduced glucose depen-
dence in its cellular interaction with GCK (Fig. 4).
Accordingly, in spite of higher fasting-state GCK activity
in the presence of P446L-hGKRP, GCK may not be
activated to the same extent by increased glucose in the
presence of this variant. This provides a mechanistic
explanation for the observation that the P446L variant is
associated with increased 2 h glucose levels but decreased
fasting glucose levels [10, 29].
Interestingly, the degree of nuclear localisation of rGKRP is
significantlyreducedcomparedwithWT-hGKRPinbothHeLa
cells and hepatocytes. Our studies assessing the localisation of
transfected rGKRP in mouse hepatocytes (nuclear/cytoplasmic
ratio of 3.37 at 5.5 mmol/l glucose) are highly consistent with
our observations of endogenous rGKRP in rat hepatocytes
(nuclear/cytoplasmic ratio of 3.44 at 5.5 mmol/l glucose;
S. Baltrusch, unpublished observations). However, the abnor-
mality in nuclear GCK sequestration for P446L-GKRP appears
to be specific to the human regulatory protein as we did not
observe a similar phenomenon with rGKRP. This is consistent
with previous studies that have established important species-
specific differences in both the regulation of human and rat
GKRP by F6P and the impact of the P446L variant on this
regulation [12–14]. Taking into account our previous assess-
ment of the interaction of rGKRP with human GCK by
FRETN analysis in COS-1 cells [21], direct interaction
determined in our experiments in living cells appeared to be
strongest between hGKRP and GCK. This is consistent with
in vitro studies highlighting hGKRP as a more potent inhibitor
of GCK than rGKRP [14]. These studies serve to
emphasise the differences between human and rat
regulatory proteins and highlight the need for use of
appropriate assays to decipher complex mutational
mechanisms driving disease associations.
It has previously been reported that glucose-dependent
GCK localisation is highly heterogeneous in rat hepatocytes
[25], thus necessitating careful analysis in living and fixed
cells. Our results comparing the glucose dependence of the
nuclear/cytoplasmic ratio for human GCK co-transfected
with rGKRP in mouse hepatocytes resulted in a ratio at
25 mmol/l that was 63% of the ratio at 5.5 mmol/l glucose.
This is consistent with the ratio calculated from the results
of Watanabe et al. [25] analysing endogenous rat GCK
(59%) and our previous results measuring the nuclear/
cytoplasmic ratio of transfected human GCK in rat
Fig. 5 Localisation of human GCK and direct interaction with WT-
hGKRP or P446L-hGKRP in primary mouse hepatocytes. Hepato-
cytes were transiently transfected with plasmids encoding ECFP-GCK
and EYFP, EYFP-WT-hGKRP or EYFP-P446L-hGKRP as indicated
and cultured in medium with 5.5 or 25 mmol/l glucose. Thereafter,
fluorescence images were taken in living cells. a Calculation of the
ECFP-GCK nuclear:cytoplasmic ratio. Data are expressed as means±
SEM of two individual experiments with a total of 9–12 cells
analysed; *p<0.05 (ANOVA/Bonferroni correction). b Calculation
of FRETN from the ECFP and EYFP emission intensities in the
nucleus and cytoplasm. Data are expressed as means±SEM of two
individual experiments with a total of 6–7 cells analysed; **p<0.01;
***p<0.001 compared with control;
††p<0.01 compared with WT
(ANOVA/Bonferroni correction). White bars, 5.5 mmol/l glucose;
black bars, 25 mmol/l glucose
120 Diabetologia (2012) 55:114–122hepatocytes (61%) [17]. Translocation of human GCK in
the presence of hGKRP has not been previously explored,
but our results suggest there are important differences
between the rat and human GKRP translocation systems,
and that regulation of translocation in humans will be
strongly dependent on the genotype at P446L. Extensive
assessment in human hepatocytes of appropriate genotype
may provide useful future insight into these questions.
In conclusion, we have demonstrated that the human
GCKR P446L variant alters the ability of GKRP to
sequester GCK in the nucleus. This observation, coupled
with our previous kinetic studies, provides a mechanistic
link between a common genetic variant associated with
diabetes risk and metabolic traits and glucose and triacyl-
glycerol metabolism.
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